Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery

Journal of Nanoparticle Research

Volumn 16, Issue 11, 2014, Pages

  Silva, A Sofia ^a,b   Tavares, Márcia T ^a   Aguiar Ricardo, Ana ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Composite nanoparticles; Dry powders; Inhalation; Nanomedicine; Spray drying; Supercritical assisted atomization

Indexed keywords

EFFLUENT TREATMENT; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POWDERS; RESPIRATORY THERAPY; SPRAY DRYING; SUPERCRITICAL FLUIDS; TARGETED DRUG DELIVERY;

COMPOSITE NANOPARTICLES; DESIGN AND DEVELOPMENT; DRY POWDERS; INHALATION; PULMONARY DRUG DELIVERY; SUPERCRITICAL ASSISTED ATOMIZATION; SUSTAINABLE PRODUCTION; SUSTAINABLE STRATEGIES;

CONTROLLED DRUG DELIVERY;

BIOPOLYMER; DIPALMITOYLPHOSPHATIDYLCHOLINE; LEUCINE; NANOCARRIER;

AEROSOL; ARTICLE; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STORAGE; DRY POWDER INHALER; FIRST PASS EFFECT; FREEZE DRYING; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; INTERNALIZATION; LUNG DISEASE; LUNG INFECTION; MACROMOLECULE; MACROPHAGE; MEDICAL NEBULIZER; MEDICATION COMPLIANCE; METASTASIS; METERED DOSE INHALER; MICROCAPSULE; NANOENGINEERING; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; SPRAY DRYING; STATIC ELECTRICITY; SUPERCRITICAL FLUID; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION;

EID: 84912571581     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-014-2602-0     Document Type: Article

References (107)

1. Adami R, Osséo LS, Reverchon E (2009) Micronization of lysozyme by supercritical assisted atomization. Biotechnol Bioeng 104:1162–1170
2. Adami R, Liparoti S, Reverchon E (2011) A new supercritical assisted atomization configuration, for the micronization of thermolabile compounds. Chem Eng J 173:55–61
3. Akiyama Y, Mori T, Katayama Y, Niidome T (2009) The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice. J Control Release 139:81–84
4. Alderborn G, Elofsson U, Elversson J, Millqvist-fureby A (2003) Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci 92:900–910
5. Al-Qadi S, Grenha A, Carrión Recio D, Seijo B, Remuñán-López C (2012) Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release 157:383–390
6. Amidi M, Pellikaan HC, de Boer AH, Crommelin DJA, Hennink WE, Jiskoot W (2008) Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur J Pharm Biopharm 68:191–200
7. Borm PJA, Kreyling W (2004) Toxicological hazards of inhaled nanoparticles—potential implications for drug delivery. J Nanosci Nanotechnol 4:521–531
8. Cabral RP (2013) Development of chitosan-based microparticles for pulmonary drug delivery. Dissertation, Univerdade Nova de Lisboa
9. Casimiro T, Barroso T, Figueiredo P, Costa E, Aguiar-Ricardo A (2011) Porous chitosan –drug formulations by scCO2-assisted atomization. In: Proceedings of 13th European meeting on supercritical fluids. http://www.isasf.net/fileadmin/files/Docs/DenHaag/HtmlDir/Papers/P68.pdf. Accessed 20 May 2014
10. Challoner P, Rodriguez C, Tarara T (2012) Tobramycin formulation for treatment of endobronchial infections European Patent 1765288 B1
11. Chattopadhyay P, Gupta RB (2001) Production of antibiotic nanoparticles using supercritical CO2 as antisolvent with enhanced mass transfer. Ind Eng Chem Res 40:3530–3539
12. Chattopadhyay P, Gupta RB (2002) Supercritical CO2 based production of magnetically responsive micro- and nanoparticles for drug targeting. Ind Eng Chem Res 41:6049–6058
13. Choi HS, Ashitate Y, Lee JH, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A (2010) Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 28:1300–1303
14. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY (2007) Particle engineering for pulmonary drug delivery. Pharm Res 24:411–437
15. ClinicalTrials.gov (2013) A clinical trial to assess the safety of a measles vaccine (dry powder) administered by two different devices (PMV-001). http://clinicaltrials.gov/show/NCT01557699. Accessed 14 Oct 2014
16. ClinicalTrials.gov (2014) Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (Non-CF BE) (RESPIRE 1). http://clinicaltrials.gov/show/NCT01764841. Accessed 14 Oct 2014
17. Couzin-Frankel J (2013) Cancer immunotherapy. Science 342(20):1432–1433
18. Crowther Labiris NR, Holbrook AM, Chrystyn H et al (1999) Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med 160:1711–1716
19. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 144:118–126
20. Cryan S-A, Sivadas N, Garcia-Contreras L (2007) In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 59:1133–1151
21. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA (2012) Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv 3:457–478
22. Dunbar CA, Concessio NM, Anthony J (1998) Evaluation of atomizer performance in production. Pharm Dev Technol 3:433–441
23. Duncan B, Kim C, Rotello VM (2010) Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 148:122–127
24. Elversson J, Millqvist-Fureby A (2005) Particle size and density in spray drying-effects of carbohydrate properties. J Pharm Sci 94:2049–2060
25. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A (2005) Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90:3287–3294
26. Gabrio BJ, Stein SW, Velasquez DJ (1999) A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 186:3–12
27. Geiser M, Quaile O, Wenk A, Wigge C, Eigeldinger-Berthou S, Hirn S, Schäffler M, Schleh C, Möller W, Mall MA, Kreyling WG (2013) Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part Fibre Toxicol 10:19–29
28. Genina N, Räikkönen H, Heinämäki J, Veski P, Yliruusi J (2010) Nano-coating of β-galactosidase onto the surface of lactose by using an ultrasound-assisted technique. AAPS PharmSciTech 11:959–965
29. Gil M, Vicente J, Gaspar F (2010) Scale-up methodology for pharmaceutical spray drying. Chem Today 28:18–22
30. Girotra P, Singh SK, Nagpal K (2013) Supercritical fluid technology: a promising approach in pharmaceutical research. Pharm Dev Technol 18:22–38
31. Gómez-Gaete C, Fattal E, Silva L, Besnard M, Tsapis N (2008) Dexamethasone acetate encapsulation into Trojan particles. J Control Release 128:41–49
32. Grenha A, Remuñán-López C, Carvalho ELS, Seijo B (2008) Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 69:83–93
33. Hadinoto K, Zhu K, Tan RBH (2007) Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm 341:195–206
34. Hardy JG, Chadwick TS (2000) Sustained release drug delivery to the lungs: an option for the future. Clin Pharmacokinet 39:1–4
35. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HD, Mulder T, McLean R, Langridge J, Papadopoulos D (2007) Physical characterization of component particles included in dry powder inhalers I. Strategy review and static characteristics. J Pharm Sci 96:1282–1301
36. Hoet PH, Brüske-Hohlfeld I, Salata OV (2004) Nanoparticles—known and unknown health risks. J Nanobiotechnol 2:12–27
37. Hu J, Dong Y, Pastorin G, Ng WK, Tan RBH (2013) Spherical agglomerates of pure drug nanoparticles for improved pulmonary delivery in dry powder inhalers. J Nanoparticle Res 15:1560–1572
38. Lai Sk, Wang Y-Y, Hanes J (2010) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 61:158–171
39. Kaur G, Narang RK, Rath G, Goyal AK (2012) Advances in pulmonary delivery of nanoparticles. Artif Cells Blood Substit Immobil Biotechnol 40:75–96
40. Kaye SR, Tol SP, Alpar HO (2009) Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. J Pharm Sci 98:4055–4068
41. Kling J (2008) Inhaled insulin’s last gasp? Nat Biotechnol 26:479–480
42. Klingler C, Müller BW, Steckel H (2009) Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm 377:173–179
43. Koushik K, Dhanda DS, Cheruvu NPS, Kompella UB (2004) Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res 21:1119–1126
44. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK (2010) Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 7:781–794
45. Laube BL, Edwards AM, Dalby RN, Creticos PS, Norman PS (1998) Respiratory pathophysiologic responses: the efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. J Allergy Clin Immunol 101:475–483
46. Li H-Y, Birchall J (2006) Chitosan-modified dry powder formulations for pulmonary gene delivery. Pharm Res 23:941–950
47. Li Y-Z, Sun X, Gong T, Liu J, Zuo J, Zhang ZR (2010) Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 27:1977–1986
48. Linsenbühler M, Wirth K-E (2005) An innovative dry powder coating process in non-polar liquids producing tailor-made micro-particles. Powder Technol 158:3–20
49. Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3:1377–1397
50. Malcolmson RJ, Embleton JK (1998) Dry powder formulations for pulmonary delivery. Pharm Sci Technolo Today 1:394–398
51. Mansour HM, Rhee Y-S, Wu X (2009) Nanomedicine in pulmonary delivery. Int J Nanomed 4:299–319
52. Martín A, Cocero MJ (2008) Micronization processes with supercritical fluids: fundamentals and mechanisms. Adv Drug Deliv Rev 60:339–350
53. Martín Á, Weidner E (2010) PGSS-drying: mechanisms and modeling. J Supercrit Fluids 55:271–281
54. Martín Á, Pham HM, Kilzer A, Kareth S, Weidner E (2010) Micronization of polyethylene glycol by PGSS (Particles from Gas Saturated Solutions)-drying of aqueous solutions. Chem Eng Process Process Intensif 49:1259–1266
55. McGlynn P, Bakale R, Sturge C (2007) Levalbuterol salt US Patent 7256310 B2 10
56. Millqvist-fureby A, Malmsten M (1999) Spray-drying of trypsin—surface characterisation and activity preservation. Int J Pharm 188:243–253
57. Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P (2011) Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91:71–81
58. Moghaddam PH, Ramezani V, Esfandi E, Vatanara A, Nabi-Meiobodi M, Darabi M, Gilani K, Najafabadi AR (2013) Development of a nano–micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol 239:478–483
59. Mohajel N, Najafabadi AR, Azadmanesh K, Vatanara A, Moazeni E, Rahimi A, Gilani K (2012) Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. Int J Pharm 423:577–585
60. Newman SP, Wilding IR (1998) Gamma scintigraphy: an in vivo technique for assessing the equivalence of inhaled products. Int J Pharm 170:1–9
61. Nolan LM, Li J, Tajber L, Corrigan OI, Healy AM (2011) Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglycate. Int J Pharm 405:36–46
62. Oberdörster G, Oberdörster E, Oberdörster J (2005) Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823–839
63. Odziomek M, Sosnowski TR, Gradoń L (2012) Conception, preparation and properties of functional carrier particles for pulmonary drug delivery. Int J Pharm 433:51–59
64. Oishi M, Tamura A, Nakamura T, Nagasaki Y (2009) A smart nanoprobe based on fluorescence-quenching PEGylated nanogels containing gold nanoparticles for monitoring the response to cancer therapy. Adv Funct Mater 19:827–834
65. Okamoto H, Nishida S, Todo H, Sakakur Y, Iida K, Danjo K (2003) Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J Pharm Sci 92:371–380
66. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H (2006) Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm Res 23:177–183
67. Packhaeuser CB, Lahnstein K, Sitterberg J, Schmehl T, Gessler T, Bakowsky U, Seeger W, Kissel T (2009) Stabilization of aerosolizable nano-carriers by freeze-drying. Pharm Res 26:129–138
68. Pasquali I, Bettini R, Giordano F (2006) Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Sci 27:299–310
69. Pilcer G, Amighi K (2010) Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392:1–19
70. Powell MC, Kanarek MS (2006) Nanomaterial health effects—part 1: background and current knowledge. Wis Med J 105:16–20
71. Pulliam B, Sung JC, Edwards DA (2007) Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv 4:651–663
72. Rehman M, Shekunov BY, York P, Lechuga-Ballesteros D, Miller DP, Tan T, Colthorpe P (2004) Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci 22:1–17
73. Restani RB, Conde J, Baptista PV, Cidade MT, Bragança AM, Morgado J, Correia I, Aguiar-Ricardo A, Bonifácio VDB (2014) Polyurea dendrimer for efficient cytosolic siRNA delivery. RSC Adv. doi:10.1039/C4RA0903G
74. Reverchon E (1999) Supercritical antisolvent precipitation of micro- and nano-particles. J Supercrit Fluids 15:1–21
75. Reverchon E (2002) Supercritical-assisted atomization to produce micro- and/or nanoparticles of controlled size and distribution. Ind Eng Chem Res 41:2405–2411
76. Reverchon E (2007) Process for the production of micro and/or nano particles US Patent 7276190 B2. 10
77. Reverchon E, Adami R (2006) Nanomaterials and supercritical fluids. J Supercrit Fluids 37:1–22
78. Reverchon E, Adami R, Caputo G (2006) Supercritical assisted atomization: Performance comparison between laboratory and pilot scale. J Supercrit Fluids 37:298–306
79. Rogueda PG, Traini D (2007) The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv 6:607–620
80. Rowe RC, Sheskey PJ, Quinn ME (2009) Handbook of pharmaceutical excipients. Pharmaceutical Press, London
81. Sadhukha T, Wiedmann TS, Panyam J (2013) Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 34:5163–5171
82. Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58:60–1030
83. Sanli D, Bozbag SE, Erkey C (2011) Synthesis of nanostructured materials using supercritical CO2: Part I. Physical transformations. J Mater Sci 47:2995–3025
84. Sinsuebpol C, Chatchawalsaisin J, Kulvanich P (2013) Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7:861–873
85. Sivadas N, O’Rourke D, Tobin A, Buckley V, Ramtoola Z, Kelly JG, Hickey AJ, Cryan SA (2008) A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm 358:159–167
86. Son Y-J, Worth Longest P, Hindle M (2013) Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm 443:137–145
87. Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, Urbanetz N, Cittero M, Schoubben A, Hippchen C, Cade D, Fuglsang A, Morais J, Borgström L, Farshi F, Seyfang KH, Hermann R, van de Putte A, Klebovich I, Hincal A (2013) Developing and advancing dry powder inhalation towards enhanced therapeutics. Eur J Pharm Sci 48:181–194
88. Stephenson GA, Forbes RA, Reutzel-Edens SM (2001) Characterization of the solid state: quantitative issues. Adv Drug Deliv Rev 48:67–90
89. Storey RA, Ingvar Y (2011) Solid state characterization of pharmaceuticals. Wiley, Hoboken
90. Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA (2009) Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 26:55–1847
91. Telko MJ, Dsc AJH (2005) Dry powder inhaler formulation. Respir Care 50:1209–1227
92. Tewa-Tagne P, Briançon S, Fessi H (2006) Spray-dried microparticles containing polymeric nanocapsules: formulation aspects, liquid phase interactions and particles characteristics. Int J Pharm 325:63–74
93. Ticehurst M, Marziano I, Kougoulos E (2014) Process for the preparation of fluticasone propionate form 1 US Patent 0141247 A1 14
94. Tolman JA, Williams RO (2010) Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm 36:1–30
95. Tonnis WF, Lexmond AJ, Frijlink HW, de Boer AH, Hinrichs WLJ (2013) Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv 10:1383–1397
96. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA (2002) Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 99:12001–12005
97. Türk M (1999) Formation of small organic particles by RESS: experimental and theoretical investigations. J Supercrit Fluids 15:79–89
98. Ungaro F, D’Angelo I, Miro A, La Rotonda MI, Quaglia F (2012) Engineered PLGA nano-and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 64:1217–1235
99. Van Der Walle C (2011) Peptide and protein delivery. Elsevier, Oxford
100. Vehring R (2008) Pharmaceutical particle engineering via spray drying. Pharm Res 25:999–1022
101. Wanakule P, Liu GW, Fleury AT, Roy K (2012) Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J Control Release 162:429–437
102. Weers J, Rao N, Huang D, Miller D, Tarara T (2013) Dry powder formulation of particles that contain two or more active ingridients for treating obstructive or inflammatory airways diseases US Patent 0319411 A1 13
103. Yang W, Peters JI, Williams RO (2008) Inhaled nanoparticles–a current review. Int J Pharm 356:239–247
104. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y (2009) Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30:1947–1953
105. Yang L, Luo J, Shi S, Zhang Q, Sun X, Zhang Z, Gong T (2013) Development of a pulmonary peptide delivery system using porous nanoparticle-aggregate particles for systemic application. Int J Pharm 451:104–111
106. Yeo S-D, Kiran E (2005) Formation of polymer particles with supercritical fluids: a review. J Supercrit Fluids 34:287–308
107. Zhang J, Wu L, Chan H-K, Watanabe W (2011) Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 63:441–455